The Pharmacy Times® Psoriasis Resource Center is a comprehensive resource for clinical news and expert insights on treatments for psoriasis.
March 28th 2023
The results of the INSPIRE trial demonstrated that 20.3% of individuals receiving risankizumab (Skyrizi) achieved clinical remission compared to 6.2% of individuals who received the placebo.
February 28th 2023
Phase 3 Data Favor Bimekizumab Over Placebo in Biologic-Naïve Patients With Psoriatic ArthritisDecember 20th 2022
All primary and ranked secondary endpoints of the study were met at week 16, which were sustained or improved through week 24 and were coupled with patient-reported improvements compared with placebo in treating psoriatic arthritis.
FDA Approves Adalimumab Biosimilar for Plaque Psoriasis, Other Chronic ConditionsDecember 16th 2022
Adalimumab-aacf (Idacio) is indicated for chronic conditions such as rheumatoid arthritis, plaque psoriasis, ulcerative colitis, psoriatic arthritis, hidradenitis suppurativa, and juvenile idiopathic arthritis.
Secukinumab Dosing Intervals Based on Treatment Response Show Safety, Efficacy in Patients with PsoriasisDecember 8th 2022
A modified secukinumab dosing regimen produced outcomes on par with currently recommended intervals in patients with moderate-to-severe psoriasis, but longer follow-ups are needed to confirm the findings.
Guselkumab Shows Long-Term Improvement in Quality of Life for Patients With Active Psoriatic ArthritisNovember 16th 2022
Guselkumab (Tremfya) is a fully human selective IL-23 inhibitor therapy FDA-approved for the treatment of adults with active psoriatic arthritis and with moderate to severe plaque psoriasis.
Study Shows Psoriasis Does Not Increase Heart Attack Risk in Patients with Kidney DiseaseOctober 19th 2022
The study confirmed that patients with psoriasis are considered to have an increased risk for both chronic kidney disease and ESRD, because inflammation plays a significant role in those conditions as well as heart disease.
Tremfya Shows Higher Skin Clearance Rates With Earlier Treatment for Plaque PsoriasisSeptember 21st 2022
Janssen’s GUIDE data demonstrate that patients treated with guselkumab less than 2 years after disease onset vs later are more likely to achieve “super-responder” at week 20 through 28.
New Data for Apremilast Show Significant Improvement in Measures of Moderate to Severe Plaque Psoriasis in ChildrenSeptember 13th 2022
It is currently indicated for the treatment of adult patients with active psoriatic arthritis and adult patients with oral ulcers associated with Behçet's Disease.
FDA Approves Spevigo for Treatment of Generalized Pustular Psoriasis Flares in AdultsSeptember 12th 2022
Boehringer Ingelheim’s monoclonal antibody inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for this indication.
FDA Approves Citrate-Free High-Concentration Humira Biosimilar HadlimaAugust 18th 2022
Adalimumab-bwwd is a tumor necrosis factor blocker indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, and plaque psoriasis.
Clinical Overview: Cyletzo, a Biosimilar Version of AdalimumabJuly 19th 2022
Indications for adalimumab include ankylosing spondylitis, Crohn disease, chronic plaque psoriasis, juvenile idiopathic arthritis, moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.